Trials / Active Not Recruiting
Active Not RecruitingNCT04557098
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 194 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teclistamab | Teclistamab will be administered SC. |
Timeline
- Start date
- 2020-09-17
- Primary completion
- 2021-11-09
- Completion
- 2027-05-28
- First posted
- 2020-09-21
- Last updated
- 2026-04-13
Locations
51 sites across 11 countries: United States, Belgium, Canada, China, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04557098. Inclusion in this directory is not an endorsement.